Cytokine-induced autoimmune disorders

Drug Safety

Volumn 17, Issue 2, 1997, Pages 93-104

  Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2;

AUTOIMMUNITY; HELPER CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID DISEASE;

EID: 0030824037     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717020-00002     Document Type: Review

References (123)

1. Fujitu S, Puri RK, Yu ZX, et al. An ultrastructural study of in vivo interactions between lymphocytes und cndothetial cells in the pathogenesis of the vascular leak syndrome induced by interleukin 2. Cancer 1991; 68 (10): 2169-74
2. Haddad J, Deny P, Munz Gotheil C, et al. Lymphoeytic sialadenitis of Sjogren's syndrome associated with chronic bepalitis C virus liver disease, Lancet 1992; 339 (8789): 321-3
3. Agnello V, Chung RT, Kaplan LM, A role for hepatitis C virus infection in type II cryoglohulinemia. N Engl J Med 1992; 327 (21): 1490-5
4. Ferri C, Greco F, Longombardo G, et al Antibodies to hepatitis C virus in patients with mixed cryoglohutinemia. Arthritis Rheum 1991; 34 (12): 1606-10
5. Preziati D, La Rosa L, Covini G. et al. Autoimmunily and thyroid functtion in patients with chronic active hepatitis treated with recombinant interteron alpha-2a. Eur J Endoerinol 1995; 132 (5):587-93
6. Vialetles B, Cuillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinam inter-leukin-2 therapy in advanced malignancies. Acta Endocrinol 1993; 129 (1): 31-8
7. Garcia Buey L, Gareia Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepalitis C, Gastroenterogy 1995; (6): 1770-7
8. Miossec P, Acting on the cytokine balance to control autoimmunity and chronic inflammation. Eur Cytokine Netw 1993; 4: 245-51
9. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev lmmunoI 1989; 7: 145-73
10. H2 subsets: doubt no more. Immunol Today 1991; 12: 256-7
11. Chomarat P, Rissoan M-C, Banchereau J, et al. Interferon γ inhibits interleukin-10 production by monoeytes. J Exp Med 1993; 177: 523-7
12. H2 lymphocytes. Eur J Dermatol 1992; 8: 601-7
13. Rapoport MJ, Jaramillo A, Zipris D, et al. Interlcukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99
14. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277-9
15. Hess AD, Jones RJ, Morris LE, et al. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. Hum Immunol 1992; 34 (3): 219-24
16. Daynes RA, Araneo BA, Dowell TA, et al. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990; 171: 979-96
17. Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type I T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346-50
18. Gonzalo JA, Cuende E, Ales Martinez. JE, et al. lnterleukin-2: a possible trigger for autoimmunity. Int Arch Allergy Immunol 1992; 97 (4): 251-7
19. Krocmer G, Martinez C, lnterleukin-2. a pro-autoimmune lymphokine that interferes with post-deletional tolerance. Semin Immunol 1992; 4 (3): 167-79
20. Nathan CF, Coordinate actions of growth factors in monocytes/ macrophages. In: Sporn MB, Roberts AB, editors. Peplide growth factors and their receptors II. Berlin: Springer-Verlag, 1990: 427-53
21. Becker JC, Dummer R, Sehwinn A, et al. Circulating intercellular adhesion molecule I in melanoma patients: induction by interlcukin 2 therapy. J Immunother 1992; 12 (2): 147-50
22. Baars JW, de Boer JP, Wagstaff J, et al. Interleukin 2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br J Haematol 1992; 82 (2): 295-301
23. Punt KC, Jansen RL, De Mulder PH, et al. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study. J Immunother 1992; 12 (4): 277-84
24. Huynh HK, Oger J, Dorovini Zis K, Interferon-beta downregulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60 (1-2): 63-73
25. Brod SA, Marshall GD Jr, Henninger EM, et al. Interferon-beta Ib treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46 (6): 1633-8
26. Realdi G, Fattovich G, Pastore G, et al. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. J Hepatol 1990: 11 Suppl. 1: S129-32
27. Kattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38-47
28. Hirashima N, Mizokami M, Onto E, et al. Chronic hepatitis C complicated by Coombs-negative hemolytic anemia during interferon treatment. Intern Med 1994; 33 (5): 300-2
29. Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic mycloid metaplasia complicated by immune hemolytic anemia. Hematol Pathol 1991; 5 (2): 83-8
30. McSweeney EN, Giles FJ, Worman CP, et al. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 1993; 85 (1): 77-83
31. Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thromhocytopenia? A case report. Ann Ital Med Int 1995; 10 (3): 193-4
32. Shrestha R, McKinley C, Bilir BM, et al. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995; 90 (7): 1146-7
33. Murakami CS, Zeller K, Bodenheimer HC Jr, et al. Idiopathic thrombocytopenic purpura during interferon alpha 2B treatment for chronic hepatitis. Am J Gastroenterol 1994; 89 (12): 2244-5
34. Durand JM, Lefevre P, Telle H, et al. Thrombocytopenic purpura and hepatitis C virus infection [letter]. Haematologica 1993; 78 (2): 135
35. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol 1994; 21 (2): 350-2
36. Wandl UB, Nagel Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Inununopathol 1992; 65 (1): 70-4
37. Bojic I, Lilic D, Radojcic C, et al. Deterioration of mixed cryoglobulinemia during treatment with interferon alpha 2a. J Gastroenterol 1994; 29(3): 369-71
38. Harle JR, Digdier P, Pelletier J, et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa [letter]. JAMA 1995; 274 (2): 126
39. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunoiherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994; 30A (8): 1209-11
40. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatite. Am J Gastroenterol 1993; 88(10): 1756-8
41. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol 1990; 126(3): 351-5
42. Fattovich G, Betterle C, Brollo L, et al. Autoantibodies during alpha interferon therapy for chronic hepatitis B. J Med Virol 1991; 34 (2): 132-5
43. Fallovich G, Betterle C, Brollo L, et al. Induction of autoantibidies during alpha interferon treatment in chronic hepatitis B. Arch Virol Suppl 1992; (4): 291-3
44. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1993; 132 (3): 474-8
45. Wandl UB, Kloke O, Nagel Hiemke M, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pre-treated patients with Ph-positive chronic myclogenous leukaemia. Br J Haematol 1992; 81 (4): 516-9
46. Silvestri F, Virgolini L, Mazzolini A, et al. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994; 79 (4): 367-70
47. Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation or thyroid autoimmunily by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 1994; 41 (5): 565-72
48. Villlisa D, Cavanna L, Berte R, et al. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995; 93 (1): 31-5
49. Lisker Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102 (6): 2155-60
50. Lim SH, Callaghan T, Goldstone AH. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Acta Haematol 1991; 85 (1): 49-50
51. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gaslroenterol 1993; 88 (2): 244-7
52. Monig H, Hauschild A. Lange S. et al. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma, Clin Investig 1994; 72 (12): 975-8
53. Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long term treatment with rccombinant interferon alpha. Clin Exp Immunol 1992; 90 (3): 363-7
54. Waguri M, Honafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diahetes Res ClinPracl 1994; 23 (1): 33-6
55. Krug J, Fritzsch J, Aust G. Induction of insulin antibodies and insulin allergy under alpha interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus: a case report. Int Arch Allergy Immunol 1995; 106 (2): 169-72
56. Schilling PJ, Kurzrock R, Kantarjian H, et al. Development of systemic lupus erylhcmatosus after interferon therapy for chronic myelogenous leukemia.Cancer 199l; 68 (7): 1536-7
57. Flores A, Olive A, Feliu E, et al. Systemic lupus erythematosus following interferon therapy (letter). Br J Rheumatol 1994; 33 (8): 787
58. Tolaymat A, Leventhal B, Sakoman A, et al Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992; 120 (3): 429-32
59. Conlon KC, Urba WJ, Smith JWD, et al. Exacerbation of symptoms of autoimmune diseuse in patients receiving alpha-interferon therapy. Cancer 1990; 65 (10): 2237-42
60. O'Connell PG, Cerber LH, Digiovanna JJ. et al. Arthritis in patients with psoriasis treated with gamma interferon. J Kheumatol 1992; 19 (1) 80-2
61. Cleveland MG, Mallory SB. Incomplete Reiter's syndrome induced by systemic interferon alpha treatment. J Am Acad Dermatol 1993; 29 (5 Pt 1): 788-9
62. Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33 (12): 806-8
63. Fsleva Lorenzo FJ, Janik JE, Fonton RG, et al. Myosilis associated with interleukin-2 therapy in a patient with metaslalic renal cell carcinoma. Cancer 1995; 76 (7): 1219-23
64. Porez A, Perella M, Pastor K, et al. Myasthenia gravis induced by alpha Interferon therapy. Am J Hematol 1995; 49(4): 365-6
65. Balocchi AP, Evoli A, Servidei S, et al. Myusthenia gravis during interferon alfa therapy. Neurology 1995; 45 (2): 382-3
66. Piccolo G, Franciolta D, Versino M, et al. My asthenia gravis in a patient with chronic active hepatitis C during interteronalpha treatment [lelter]. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348
67. Mase G, Zorzon M, Biasutti E, et al. Development of myasthenia gravis during Interferon alpha treatment for anti HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348-9
68. Schwarzer A, Schulze E, Leiblein S, et al. Cuillain Barre syndrome, a possible side effect of buffy coat transfusion and IFN alpha therapy in relapsed ('Ml. after bone marrow transplantation [letter]. Ann Oncol 1995; 6 (6): 617
69. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha interferon. Ann Intern Med 1992; 116 (1): 51-3
70. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenlerology 1992; 102 (4 Pt 1): 1406-8
71. Marcellin P, Colin JE, Boyer N, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha interferon [letter]. Lancet 1991; 338 (8770): 828
72. Czaju AJ, Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994; 23 (3): 547-66
73. Ferri C, Longombardo G, La Civita L, et al. Hepatitis C virus autoimmune liver disease and cryoglobulinaemic hepatitis. J Hepatol 1992; 16 (1-2): 242-3
74. Heintges T, Niederau C. Differential ion between autoimmune hepatitis und hepatitis C virus-related liver disease. Z Gastroenterol 1993; 31 (5): 285-8
75. Muratori L, Lenzi M, Catuleta M, et al. Inlerferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21 (2): 199-203
76. Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995; 40 (8): 1842-4
77. Ariad S, Song E, Cohen R, et al. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother 1992; 4 (3): 139-42
78. D' Amico E, Paroli M, Fratelli V, et al. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40 ( 10): 2113-6
79. Maeda T, Onishi S, Miura T, et al. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C, Dig Dis Sci 1995; 40 (6): 1226-30
80. Browett PJ, Nelson J, Tiwari S, et al. Graft-versus-host disease following interferon therapy for relapsed chronic mycloid leukaemia post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 (4): 641-4
81. Dousset B, Conti F, Houssin D, et al. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N Engl J Med 1994; 330 (16): 1160-1
82. Gadano AC, Mosnier JF, Durand F, et al. Alpha Interferon induced rejection of a hepatitis C virus infected liver allograft tolerated with a low dusage immunosupprcssive regimen. Transplantation 1995; 59 (11): 1627-9
83. Magnone M, Holley JL, Shapiro R, et al. Interferon alpha induced acute renal allograft rejection. Transplantation 1995; 59 (7): 1068-70
84. Min AD, Bodenheimer HC Jr. Does interferon precipitate rejection of liver allografts? Hepatology 1995; 22 (4 Pt 1): 1333-5
85. Sacchi S, Kanlarjian H, O'Bricn S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myclogenous leukemia. J Clin Oncol 1995; 13 (9): 2401-7
86. Imaguwa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metah 1995; 80 (3): 922-6
87. Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossovercantrolled trial. Blood 1993; 81 (5): 1132-6
88. Ferri C, Murzo E, Longombardo G, et al. Alpha interferon in the treatment of mixed cryoglobulinaemia patients. Eur J Cancer 1991; 27 Suppl. 4: 81S-2S
89. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-80
90. Ballmer Weber BK, Dummer R, Rung E, et al. lnterlcukin-2 induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 1995; 71 (1): 78-82
91. Ogilvic AC, Baars JW, Eerenherg AJ, et al. A pilot study to evaluate the effects of CI esterase inhibitor on the toxicity of high dose interleukin-2. Br J Cancer 1994; 69 (3): 596-8
92. Lissoni P, Barni S, Cattaneo G, et al. Activation of the complement system during immunolberapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers 1990; 5 (4): 195-7
93. Gaspari AA, Autoimmunity as a complication of interleukin-2 immunotherapy: many unanswered questions [comment]. Arch Dermatol 1994; 130 (7): 894-8
94. Massarotti EM, Liu NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high dose interleukin-2 for malignancy. Am J Med 1992; 92 (6): 693-7
95. Finger DR, Plotz PH, Heywood G, Myositis following treatment with high dose interleukin 2 for malignancy [letter]. J Rheumatol 1995; 22 (11): 2188
96. Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68: 2384-90
97. Perez R, Padavic K, Krigel R, et al. Antierythrocyte autoantibody formation after therapy with interleukin 2 and gamma interferon. Cancer 1991; 67 (10): 2512-7
98. Puduvalli VK, Sella A, Austin SG. et al. Carpal tunnel syndrome associated with interleukin 2 therapy. Cancer 1996; 77 (6): 1189-92
99. Dummer R, Miller K, Eilles C, et al. The skin: an immunoreaclive target organ during interleukin 2 administration? Dermatologica 1991; 183 (2): 95-9
100. Baars JW, Wagstaff J, Hack CE, et al. Angioneurotic oedema and urticaria during therapy with interleukin 2 (1L2). Ann Oncol 1992; 3 (3): 243-4
101. Baars JW, Coenen JL, Wagstaff J, et al. Lobular panniculitis after subcutaneous administration of interleukin 2 (IL-2), and its exacerbation during intravenous therapy with IL-2. Br J Cancer 1992; 66 (4): 698-9
102. Heinzcr H, Huland E, Huland H. Adverse reaction to contrast material in a patient treated with local interleukin 2 [letter]. Am J Roentgenol 1992: 158 (6): 1407
103. Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 1995; 87 (12): 915-22
104. Zukiwski AA, David CL, Coan J, et al. Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration. Cancer 1990; 65 (7): 1521-4
105. Puett DW, Fuchs HA. Rapid exacerbation of seleroderma in a patient treated with interleukin 2 and lymphokinc-activated killer cells for renal cell carcinoma. J Rheumatol 1994; 21 (4): 752-3
106. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neural 1996; 39 (3): 285-94
107. Kung AW. Jones BM, Lai CL, Effects of interferon-gamma therapy on thyroid function. T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinal Metab 1990: 71(5): 1230-4
108. Bobbio Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Surcoidosis 1995; 12 (2): 140-2
109. Sampaio HP, Moreira AL, Sarno EN. et al. Prolonged treatment with recombinant interfcron gamma induces erythema nodosum leprosum in Iepromatous leprosy patients. J Exp Med 1992; 175 (6): 1729-37
110. Seitz M, Franke M, Kirchner H. Induction of ami nuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant Interferon gamma. Ann Rheum Dis 1988; 47: 642-4
111. Cannon GW, Emkey RD, Denes A, et al. Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 1993; 20 (11): 1867-73
112. Myers LW, Ellison GW, The peculiar difficulties of therapeutic trials fur multiple sclerosis. Neural Clin 1990; 8 (1): 119-41
113. Hoshirna Y. Moriuchi J. Nukumuni Y. et al. CD4+ T cell mediated leukopenia of Felly's syndrome successfully treated with granulocyte colony stimulating factor and methotrexate. Arthritis Rheum 1994; 37 (2): 298-9
114. de Vrics EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy [letter]. Lancet 1991; 338 (8765): 517-8
115. Hayat SQ, Hearth Holmes M, Wolf RE, Flare of arthritis with successful treatment of Felty's syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 1995; 14 (2): 211-2
116. Kiely PD, Bruckner FE, Acute arthritis following Interferon alpha therapy. Br J Rheumatol 1994; 33 (5): 502-3
117. Vidarsson B, Geirsson AJ, Onundarson PT, Reactivation of rheumatoid arthritis and development of Ieukocytoclastic vasculitis in a patient receiving granuloeyte colony stimulating factor for Felly's syndrome. Am J Med 1995; 98 (6): 589-91
118. McMullin MF, Finch MB. Felly's syndrome treated with rhGCSF associated with flare of arthritis and skin rash. Clin Rheumalol 1995; 14 (2): 204-8
119. Yasudu M, Kihara T, Wada T, et al. Granulocyte colony stimulating factor induction of improved Ieukocytopenia with inflammatory tiare in a Felly's syndrome patient. Arthritis Rheum 1994 37 (1): 145-6
120. Storek J, Glaspy JA, Grody WW, et al. Adult onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol 1993; 43 (2): 139-43
121. Bhalla K, ROSS R, Jeter E, et al. G-CSF improves granulocytopenia in Felty's syndrome without flare-up of arthritis. Am J Hematol 1993; 42 (2): 230-1
122. Ronnblom LE, Alm GV, Oherg KE, Autoimmunity after alphainterferon therapy for malinant carcinoid tumors. Ann Intern Mod 1991; 115 (3): 178-83
123. Miosxec P, Chomarat P, Dechanel J. Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996; 17: 170-3